Press Releases

May 29, 2020
Athenex Presents Interim Data from Oral Paclitaxel Phase II Study in Cutaneous Angiosarcoma at ASCO20 Virtual Scientific Program
Data are featured as an ASCO poster presentation and will be part of the Sarcoma Highlights Session on Sunday, May 31, 2020 at 3:30pm ET BUFFALO, N.Y. , May 29, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and
Printer Friendly Version 
May 19, 2020
Athenex Announces Participation in the 2020 RBC Capital Markets Global Healthcare Virtual Conference
BUFFALO, N.Y. , May 19, 2020 (GLOBE NEWSWIRE) -- Athenex , Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will participate in
Printer Friendly Version 
May 07, 2020
Athenex, Inc. Reports First Quarter Ended March 31, 2020 Financial Results and Provides Corporate Update
Regulatory filings for tirbanibulin ointment for actinic keratosis submitted to both FDA and EMA Oral Paclitaxel NDA submission is on track 2020 product sales guidance re-affirmed Conference call & webcast today at 8:00am Eastern Time BUFFALO, N.Y. , May 07, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc.
Printer Friendly Version 
April 29, 2020
Athenex Announces Acceptance of Oral Paclitaxel Phase II Study in Angiosarcoma Abstract at ASCO20 Virtual Scientific Program
BUFFALO, N.Y. , April 29, 2020 (GLOBE NEWSWIRE) -- Athenex , Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that an abstract for its ongoing
Printer Friendly Version 
April 23, 2020
Athenex, Inc. to Report First Quarter 2020 Earnings Results on May 7, 2020
BUFFALO, N.Y. , April 23, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release first quarter
Printer Friendly Version 
April 09, 2020
Athenex Provides an Update on Oral Paclitaxel FDA Meeting
BUFFALO, N.Y. , April 09, 2020 (GLOBE NEWSWIRE) -- Athenex , Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it recently participated in
Printer Friendly Version 
March 13, 2020
Athenex Provides a Corporate Update
BUFFALO, N.Y. , March 13, 2020 (GLOBE NEWSWIRE) -- Athenex , Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today provides an update on the Company’s
Printer Friendly Version 
March 09, 2020
Athenex Announces FDA Acceptance for Filing of U.S. NDA for Tirbanibulin Ointment in Actinic Keratosis
PDUFA date of December 30, 2020 BUFFALO, N.Y. , March 09, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced today
Printer Friendly Version 
March 02, 2020
Athenex’s Partner Almirall Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Tirbanibulin Ointment in Actinic Keratosis
BUFFALO, N.Y. , March 02, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, provided an update today that its partner,
Printer Friendly Version 
February 27, 2020
Athenex, Inc. Reports Fourth Quarter and Year Ended December 31, 2019 Financial Results and Provides Corporate Update
Tirbanibulin ointment NDA for actinic keratosis was submitted Oral Paclitaxel NDA submission is on track; Final FDA meeting scheduled for early April Presentation of Oral Paclitaxel Phase 3 results at SABCS received broad positive reception 43% y/y increase in product revenue and 14% y/y increase
Printer Friendly Version 
February 25, 2020
Athenex Announces Participation at the Cowen 40th Annual Health Care Conference
BUFFALO, N.Y. , Feb. 25, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today announced that management will present at the Cowen 40 th Annual
Printer Friendly Version 
February 06, 2020
Athenex, Inc. to Report Fourth Quarter and Full Year 2019 Earnings Results on February 27, 2020
BUFFALO, N.Y. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today announced that it will release fourth quarter and full year 2019
Printer Friendly Version 
February 03, 2020
Athenex CEO Informs Shareholders of Unrelated Matter Regarding Past Board Membership at Porton Pharma
BUFFALO, N.Y. , Feb. 03, 2020 (GLOBE NEWSWIRE) -- Today, Dr. Johnson Lau , Chairman and Chief Executive Officer of Athenex , Inc. (Nasdaq: ATNX), informed shareholders he received a notice of a proposed administrative fine of RMB 100,000 (approximately $14,300 ) from the China Securities Regulatory
Printer Friendly Version